Philippe Clevenbergh

Author

Also Known As

Anne-Catherine Gerard, Isabelle Buelens, Marijke Reynders, P Clevenbergh, P. Clevenbergh, Philippe Albert Clevenbergh, Philippe Clevenbergh, philippe clevenbergh

100

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Hôpital Lariboisière Hôpital l'Archet Centre Hospitalier Universitaire Brugmann Centre Hospitalier Universitaire de Nice Université Libre de Bruxelles

About

Philippe Clevenbergh is an author at Hôpital Lariboisière specializing in medicine, hiv, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	2.1K
2	Public Health	5	5	411
3	Health Sciences	2	2	802
4	Social Sciences	1	1	23
5	Cell Biology	1	1	19

Philippe Clevenbergh

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial J. Durant, Philippe Clevenbergh, Philippe Halfon, The Lancet Health SciencesTreatment And PreventionHuman RetrovirusPharmacologyClinical Trials	1999	761
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu, The Lancet Infectious Diseases AntibioticsRespiratory InfectionSepsisExtended-infusion MeropenemNon-inferiority Trial	2020	432
The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan Victor DeGruttola, Lynn P. Dix, Richard T. D’Aquila, Antiviral Therapy PharmacotherapyAntiviral DrugDrug ResistanceProspective StudiesHuman Retrovirus	2000	330
Impact of Infectious Diseases Specialists and Microbiological Data on the Appropriateness of Antimicrobial Therapy for Bacteremia B. Byl, Philippe Clevenbergh, Frédérique Jacobs, Clinical Infectious Diseases Oral AntibioticsBlood Culture ResultsAntimicrobial SusceptibilityAntibioticsEmpirical Treatment	1999	265
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study J. Durant, Philippe Clevenbergh, R. Garraffo, AIDS	2000	223
Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing Anne–Mieke Vandamme, Anders Sönnerborg, Mounir Ait‐Khaled, Antiviral Therapy PharmacotherapyResistance TestingClinical UseDrug ResistanceTranslational Medicine	2004	144
Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Marianne Savès, François Raffi, Philippe Clevenbergh, Antimicrobial Agents and Chemotherapy	2000	115
Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up Philippe Clevenbergh, J. Durant, Philippe Halfon, Antiviral Therapy	2000	114
Skin lightening and its complications among African people living in Paris A. Petit, Cécile Cohen-Ludmann, Philippe Clevenbergh, Journal of the American Academy of Dermatology Global HealthSkin LighteningSkin PharmacologyDermatologyAfrican People	2006	94
PharmAdapt Philippe Clevenbergh, R. Garraffo, J. Durant, AIDS	2002	93

Page 1